Langerhans cell histiocytosis (LCH) and Erdheim–Chester disease (ECD) are rare histiocytic disorders in the L (Langerhans) group diseases. They range from self-limited benign diseases to lethal disseminated forms.
Methods
This retrospective study was conducted in 3 tertiary hospitals in Saudi Arabia and Brazil. Histopathological records were searched for all patients diagnosed with ocular and periocular histiocytic disorders from January 1993 to December 2018. Histopathological slides and medical files were reviewed for data collection and simple analysis of demographics, clinical manifestations, and management. The relevant literature is reviewed.
Results
Twenty-two eyes of 18 patients with biopsy-proven histiocytic disorders in the L group were included. Female-to-male ratio was 1.25:1. Average age at presentation was 14 years (range, 1–54). LCH was diagnosed in 14 eyes, while eight eyes had ECD. All LCH cases were unilateral and confined to the bone as cases of eosinophilic granuloma (EG), while patients with ECD were bilateral. Commonest presentations in EG and ECD were eyelid swelling (85.7%) and periocular xanthomas (75%), respectively. Orbit was involved in 100% of EG cases, with bony erosion in 54.5%. Relevant systemic involvement was found in 100% of ECD and 21% of EG cases. Surgical intervention was needed in 16 of the 22 eyes (72.7%). All EG and 25% of patients with ECD required surgical excision.
Conclusions
Histiocytic disorders are a rare group of diseases, including the L group. Relevant systemic associations require specific and selective therapy. A high clinical index and multidisciplinary collaboration are essential for the proper evaluation and management of these patients.
LichtensteinL. Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Schuller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol1953; 56: 84–102.
Writing Group of the Histiocyte Society. Histiocytosis syndromes in children. Lancet (London, England)1987; 1: 208–209.
4.
FavaraBEFellerACPauliM, et al.Contemporary classification of histiocytic disorders. The WHO committee on histiocytic/Reticulum cell proliferations. Reclassification working group of the histiocyte society. Med Pediatr Oncol1997; 29: 157–166.
5.
EmileJFAblaOFraitagS, et al.Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood2016; 127: 2672–2681.
6.
HandA. Polyuria and tuberculosis. Arch Pediatr1893; 10: 673–675.
7.
GauravGMarkLHMathewC, et al.Erdheim-Chester disease: consensus recommendations for the evaluation, diagnosis, and treatment in the molecular era. Blood2020 May 28; 135: 1929–1945.
8.
HarrisGJ. Langerhans cell histiocytosis of the orbit: a need for interdisciplinary dialogue. Am J Ophthalmol2006; 141: 374–378.
9.
LamSReddyGDMayerR, et al. Eosinophilic granuloma/Langerhans cell histiocytosis: pediatric neurosurgery update. Surg Neurol Int2015; 6(Suppl 17): S435–S439. I
10.
DenaroLLongoUGPapaliaR, et al.Eosinophilic granuloma of the pediatric cervical spine. Spine2008; 33: E936–E941.
11.
KasperEMAguirre-PadillaDHAlterRY, et al.Histiocytosis X: characteristics, behavior, and treatments as illustrated in a case series. Surg Neurol Int2011; 2: 57.
12.
MeyerJSDe CamargoB. The role of radiology in the diagnosis and follow-up of Langerhans cell histiocytosis. Hematol Oncol Clin North Am1998; 12: 307–326.
13.
DemirciHShieldsCLShieldsJA, et al.Bilateral sequential orbital involvement by eosinophilic granuloma. Arch Ophthalmol (Chicago, Ill: 1960)2002; 120: 978–979.
14.
WooKIHarrisGJ. Eosinophilic granuloma of the orbit: understanding the paradox of aggressive destruction responsive to minimal intervention. Ophthal Plast Reconstr Surg2003; 19: 429–439.
15.
AricoMGirschikofskyMGenereauT, et al.Langerhans cell histiocytosis in adults. Report from the international registry of the histiocyte society. Eur J Cancer (Oxford, England: 1990)2003; 39: 2341–2348.
16.
HamreMHedbergJBuckleyJ, et al.Langerhans cell histiocytosis: an exploratory epidemiologic study of 177 cases. Med Pediatr Oncol1997; 28: 92–97.
17.
LamanJDLeenenPJAnnelsNE, et al.Langerhans-cell histiocytosis “insight into DC biology”. Trends Immunol2003; 24: 190–196.
18.
Guyot-GoubinADonadieuJBarkaouiM, et al.Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer2008; 51: 71–75.
19.
StalemarkHLaurencikasEKarisJ, et al.Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer2008; 51: 76–81.
20.
AlstonRDTatevossianRGMcNallyRJ, et al.Incidence and survival of childhood Langerhans cell histiocytosis in Northwest England from 1954 to 1998. Pediatr Blood Cancer2007; 48: 555–560.
21.
SalottiJANanduriVPearceMS, et al.Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child2009; 94: 376–380.
22.
MaccheronLJMcNabAAElderJ, et al.Ocular adnexal Langerhans cell histiocytosis clinical features and management. Orbit (Amsterdam, Netherlands)2006; 25: 169–177.
23.
LaurencikasEGavhedDStalemarkH, et al.Incidence and pattern of radiological central nervous system Langerhans cell histiocytosis in children: a population based study. Pediatr Blood Cancer2011; 56: 250–257.
24.
VosoghiHRodriguez-GalindoCWilsonMW. Orbital involvement in langerhans cell histiocytosis. Ophthal Plast Reconstr Surg2009; 25: 430–433.
25.
JubranRFMarachelianADoreyF, et al.Predictors of outcome in children with Langerhans cell histiocytosis. Pediatr Blood Cancer2005; 45: 37–42.
26.
AllenCELiLPetersTL, et al.Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol (Baltimore, Md: 1950)2010; 184: 4557–4567.
27.
AllenCEMeradMMcClainKL. Langerhans-cell histiocytosis. N Engl J Med2018; 379: 856–868.
28.
Badalian-VeryGVergilioJADegarBA, et al.Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood2010; 116: 1919–1923.
29.
LevyJMonosTKapelushnikJ, et al.Ophthalmic manifestations in Langerhans cell histiocytosis. Isr Med Assoc J: IMAJ2004; 6: 553–555.
30.
GunduzKPalamarMParmakN, et al.Eosinophilic granuloma of the orbit: report of two cases. J AAPOS2007; 11: 506–508.
31.
WeissgoldDJWulcAEFrayerWC,et al.Eosinophilic granuloma of the eyelid. Ophthal Plast Reconstr Surg1994; 10: 160–162.
32.
MelamudAEfratMSovaY, et al.Epibulbar nodule as a symptom of Langerhans cell histiocytosis. Arch Ophthalmol (Chicago, Ill: 1960)2002; 120: 1400–1401.
33.
SitaulaRKKhatriA. Langerhans cell histiocytosis with hemorrhagic uveitis and exudative retinal detachment. Int Med Case Rep J2018; 11: 65–68.
34.
HauptRMinkovMAstigarragaI, et al.Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer2013; 60: 175–184.
35.
SinghSKalikiSReddy PalkondaVA, et al.Langerhans cell histiocytosis of the orbit: a study of eight cases. Oman J Ophthalmol2018; 11: 134–139.
CavallazziRHiraniAVasuTS, et al.Clinical manifestations and treatment of adult-onset asthma and periocular xanthogranuloma. Can Respir J2009; 16: 159–162.
38.
SongAJohnsonTEDubovySR, et al.Treatment of recurrent eosinophilic granuloma with systemic therapy. Ophthal Plast Reconstr Surg2003; 19: 140–144.
39.
BinningMJBrockmeyerDL. Novel multidisciplinary approach for treatment of langerhans cell histiocytosis of the skull base. Skull Base: Official J North Am Skull Base Soc2008; 18: 53–58.
40.
WladisEJTomaszewskiJEGausasRE. Langerhans cell histiocytosis of the orbit 10 years after involvement at other sites. Ophthal Plast Reconstr Surg2008; 24: 142–143.
41.
WirtschafterJDNesbitMAndersonP, et al.Intralesional methylprednisolone for Langerhans’ cell histiocytosis of the orbit and cranium. J Pediatr Ophthalmol Strabismus1987; 24: 194–197.
42.
HarrisGJWooKI. Eosinophilic granuloma of the orbit: a paradox of aggressive destruction responsive to minimal intervention. Trans Am Ophthalmol Soc2003; 101: 93–103; discussion 103–5.
43.
ImashukuSKinugawaNMatsuzakiA, et al.Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems. Int J Hematol2009; 90: 506–512.
44.
HerwigMCWojnoTZhangQ, et al.Langerhans cell histiocytosis of the orbit: five clinicopathologic cases and review of the literature. Surv Ophthalmol2013; 58: 330–340.
45.
GunduzAKTemelE. Histiocytic lesions of the orbit: a study of 9 cases. Saudi J Ophthalmol2018; 32: 40–44.
46.
LiebermanPHJonesCRSteinmanRM, et al.Langerhans cell (eosinophilic) granulomatosis. A clinicopathologic study encompassing 50 years. Am J Surg Pathol1996; 20: 519–552.
47.
Escardo-PatonJANealJLaneCM. Late recurrence of Langerhans cell histiocytosis in the orbit. Br J Ophthalmol2004; 88: 838–839.
48.
KilpatrickSEWengerDEGilchristGS, et al.Langerhans’ cell histiocytosis (histiocytosis X) of bone. A clinicopathologic analysis of 263 pediatric and adult cases. Cancer1995; 76: 2471–2484.
